Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVO NYSE:OGE NASDAQ:OMER NASDAQ:QURE NASDAQ:SDST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$49.49+0.0%$45.57$35.12▼$71.79$220.96B0.7710.27 million shs6.31 million shsOGEOGE Energy$48.67+0.0%$47.87$41.69▼$50.13$10.04B0.531.27 million shs1.34 million shsOMEROmeros$10.28$11.13$3.34▼$17.65$744.02M2.551.93 million shs1.09 million shsQUREuniQure$42.63$33.03$8.73▼$71.50$2.69B0.92.96 million shs1.14 million shsSDSTStardust Power$1.72$2.03$1.52▼$7.67$18.20M0.55206,705 shs294,621 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S0.00%-1.78%+12.72%+30.34%-28.21%OGEOGE Energy0.00%-1.46%+1.85%+0.15%+9.88%OMEROmeros0.00%+10.78%+17.75%-9.67%+181.64%QUREuniQure0.00%+1.96%+54.62%+137.89%+196.04%SDSTStardust Power0.00%+1.18%-6.52%-36.76%-31.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$49.49+0.0%$45.57$35.12▼$71.79$220.96B0.7710.27 million shs6.31 million shsOGEOGE Energy$48.67+0.0%$47.87$41.69▼$50.13$10.04B0.531.27 million shs1.34 million shsOMEROmeros$10.28$11.13$3.34▼$17.65$744.02M2.551.93 million shs1.09 million shsQUREuniQure$42.63$33.03$8.73▼$71.50$2.69B0.92.96 million shs1.14 million shsSDSTStardust Power$1.72$2.03$1.52▼$7.67$18.20M0.55206,705 shs294,621 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S0.00%-1.78%+12.72%+30.34%-28.21%OGEOGE Energy0.00%-1.46%+1.85%+0.15%+9.88%OMEROmeros0.00%+10.78%+17.75%-9.67%+181.64%QUREuniQure0.00%+1.96%+54.62%+137.89%+196.04%SDSTStardust Power0.00%+1.18%-6.52%-36.76%-31.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.17Hold$65.5632.48% UpsideOGEOGE Energy 2.36Hold$49.201.10% UpsideOMEROmeros 2.83Moderate Buy$38.00269.65% UpsideQUREuniQure 2.65Moderate Buy$64.1750.52% UpsideSDSTStardust Power 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest QURE, NVO, OGE, OMER, and SDST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026NVONovo Nordisk A/S HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/29/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.006/26/2026QUREuniQure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/26/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $33.006/25/2026QUREuniQure MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $68.006/24/2026OGEOGE Energy Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$50.006/19/2026NVONovo Nordisk A/S Nordea Equity ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy6/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.00(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$327.80B0.67$4.69 per share10.56$6.58 per share7.52OGEOGE Energy$3.27B3.08$5.12 per share9.51$24.71 per share1.97OMEROmeros$9.89M75.21$1.87 per share5.49($1.71) per share-6.01QUREuniQure$16.10M167.00N/AN/A$3.19 per share13.36SDSTStardust PowerN/AN/AN/AN/A($0.59) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$15.51B$4.2611.6215.134.5137.23%63.31%22.19%8/5/2026 (Estimated)OGEOGE Energy$470.70M$2.2421.7318.793.6014.03%9.47%3.20%7/29/2026 (Estimated)OMEROmeros-$3.35M$0.7014.69146.86N/AN/A-102.16%64.87%8/13/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)SDSTStardust Power-$15.72M-$2.00N/AN/AN/AN/AN/A-161.57%8/12/2026 (Estimated)Latest QURE, NVO, OGE, OMER, and SDST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026NVONovo Nordisk A/S$0.82N/AN/AN/A$10.99 billionN/A8/4/2026Q2 2026QUREuniQure-$0.8261N/AN/AN/A$5.45 millionN/A7/29/2026Q2 2026OGEOGE Energy$0.59N/AN/AN/A$770.08 millionN/A5/14/2026Q1 2026SDSTStardust Power-$0.39-$0.53-$0.14-$0.53$1.00 millionN/A5/13/2026Q1 2026OMEROmeros-$0.40-$0.24+$0.16$0.62$4.19 million$9.89 million5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million4/28/2026Q1 2026OGEOGE Energy$0.24$0.24N/A$0.24$616.02 million$752.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$1.743.52%+21.74%40.85%N/AOGEOGE Energy$1.703.49%+1.48%75.89%18 YearsOMEROmerosN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASDSTStardust PowerN/AN/AN/AN/AN/ALatest QURE, NVO, OGE, OMER, and SDST DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/14/2026OGEOGE Energyquarterly$0.42503.52%7/6/20267/6/20267/31/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.590.790.56OGEOGE Energy1.090.660.40OMEROmerosN/A3.033.03QUREuniQure0.3310.4010.40SDSTStardust PowerN/A0.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%OGEOGE Energy71.84%OMEROmeros48.79%QUREuniQure78.83%SDSTStardust Power32.79%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%OGEOGE Energy0.57%OMEROmeros10.50%QUREuniQure4.65%SDSTStardust Power55.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableOGEOGE Energy2,248206.37 million205.20 millionOptionableOMEROmeros21072.38 million64.78 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableSDSTStardust PowerN/A10.58 million4.73 millionN/AQURE, NVO, OGE, OMER, and SDST HeadlinesRecent News About These CompaniesStardust Power (NASDAQ:SDST) Shares Up 6.5% - Time to Buy?July 10 at 3:01 AM | americanbankingnews.comStardust Power Plans Transition in Legal LeadershipJuly 2, 2026 | tipranks.comStardust Power Inc. Begins Site Engineering Activities for Lithium Refinery in Muskogee, OklahomaJune 16, 2026 | quiverquant.comQStardust Power Advances Execution Readiness at Muskogee Lithium RefineryJune 16, 2026 | globenewswire.comStardust Power joins Department of Energy-backed lithium extraction programJune 3, 2026 | mining.comStardust Power Included in DOE-Funded Lithium InitiativeJune 2, 2026 | globenewswire.comStardust Power (NASDAQ:SDST) CEO Sells $223,290.86 in StockMay 29, 2026 | insidertrades.comChris Edward Celano Sells 25,975 Shares of Stardust Power (NASDAQ:SDST) StockMay 22, 2026 | insidertrades.comStardust Power Inc Ordinary Shares SDSTMay 21, 2026 | morningstar.comMStardust Power Inc (SDST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...May 15, 2026 | finance.yahoo.comStardust Power Inc. (SDST) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 14, 2026 | seekingalpha.comStardust Power Announces Q1 2026 Financial ResultsMay 14, 2026 | globenewswire.comStardust Power (SDST) Secures a $150 Million Framework for Its Oklahoma Lithium RefineryMay 8, 2026 | insidermonkey.comStardust Power Announces Q1 2026 Earnings Release Date, Conference CallMay 7, 2026 | globenewswire.comStardust Power Receives Nasdaq Noncompliance Delisting NoticeApril 30, 2026 | tipranks.comStardust Power Secures Institutional Investment Framework Supporting Up to $150 Million InvestmentApril 22, 2026 | markets.businessinsider.comStardust Power Secures Major Lithium Refinery Financing FrameworkApril 20, 2026 | tipranks.comStardust Power Inc. Signs Letter of Intent for $150 Million Project-Level Financing for Lithium Refinery in OklahomaApril 20, 2026 | quiverquant.comQStardust Power Inc. Secures Letter of Intent for Up to $150 Million Project Financing for Lithium Refinery in OklahomaApril 20, 2026 | quiverquant.comQStardust Power expands US lithium supply pipeline for Oklahoma refineryApril 14, 2026 | mining.comMade in the USA: Stardust Power’s 18% Breakout...January 21, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe SpaceX Sell-Off May Be More Than a Market OverreactionBy Jeffrey Neal Johnson | June 24, 2026SpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026Why Kroger’s Pullback Could Be a Gift for Patient InvestorsBy Thomas Hughes | June 19, 2026How Does D-Wave's New Simulator Change the Quantum Computing Landscape?By Nathan Reiff | June 23, 2026Qualcomm’s Investor Day Just Changed the Growth Story ForeverBy Sam Quirke | June 29, 2026QURE, NVO, OGE, OMER, and SDST Company DescriptionsNovo Nordisk A/S NYSE:NVO$49.49 +0.01 (+0.01%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$49.31 -0.18 (-0.36%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.OGE Energy NYSE:OGE$48.67 +0.02 (+0.03%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$48.87 +0.20 (+0.42%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OGE Energy Corp., together with its subsidiaries, operates as an energy services provider in the United States. The company generates, transmits, distributes, and sells electric energy. In addition, it provides retail electric service to approximately 896,000 customers, which covers a service area of approximately 30,000 square miles in Oklahoma and western Arkansas; and owns and operates coal-fired, natural gas-fired, wind-powered, and solar-powered generating assets. OGE Energy Corp. was founded in 1902 and is headquartered in Oklahoma City, Oklahoma.Omeros NASDAQ:OMER$10.28 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$10.34 +0.06 (+0.54%) As of 05:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.uniQure NASDAQ:QURE$42.63 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$42.57 -0.06 (-0.14%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Stardust Power NASDAQ:SDST$1.72 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.70 -0.01 (-0.87%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stardust Power Inc. is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
